期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀对Krüppel样转录因子2在载脂蛋白E基因敲除小鼠中表达的影响 被引量：2

The effect of atorvastatin on the expression of Krüppel-like factor 2 in apolipoprotein E gene knockout mice
原文传递
导出
摘要 目的探讨阿托伐他汀对Krüppel样转录因子2(KLF2)在载脂蛋白E基因敲除小鼠中表达的影响。方法研究采用载脂蛋白E基因敲除小鼠,随机分为对照组和干预组,干预药物采用阿托伐他汀10mg/(kg·d),药物干预8周后分别用半定量RT-PCR,Westernblot,免疫组化检测主动脉KLF2的表达,HE染色切片计算斑块的相对面积。结果 KLF2在各个水平的表达干预组高于对照组[mRNA水平(0.85±0.01)比(0.48±0.02),蛋白水平(1.84±0.11)比(1.45±0.14);组织水平(0.40±0.06)比(0.26±0.09);均P<0.05];斑块相对面积:干预组(0.26±0.09)小于对照组(0.41±0.04)(P<0.01)。结论阿托伐他汀上调载脂蛋白E基因敲除小鼠颈动脉内KLF2表达。 Objective To explore the effect of atorvastatin on the expression of Kruppel-like factor 2 in apolipopro- tein E （ApoE） gene knockout mice. Methods ApoE gene knockout （ApoE-/- ） mice were randomized into intervention group and control group. Atorvastatin [-10 mg/（kg· d）] was applied as the interventional drug. After 8 weeks of intervention, KLF2 gene and itsprotein expression were measured by semiquantitative real-time PCR, immunohistochemistry, and Western blot. HE staining was used to caeulat the relative area of palque. Results The expression of KLF2 in intervention group was higher than control group on different levels I-mRNA（0. 85 ± 0.01） vs （0.48±0.02）, protein （1.84±0.11） vs （1. 45±0.14） and histology （0. 40±0.06） vs {0. 264-0.09）, all P〈0.05-1, and the relative plague area of intervention group was significantly less than that of control group 1-（0. 264-0. 09） vs （0. 41±0.04}, P〈0. 01]. Conehtsion Atorvastatin can up-regulat KLF2 in aorta of ApoE-/- mice.
作者 周晓斌 杨丽霞 郭瑞威 齐峰 石燕昆 衡旭华 梁星
机构地区 成都军区昆明总医院心内科 昆明医科大学成都军区昆明总医院临床学院
出处 《中华高血压杂志》 CAS CSCD 北大核心 2012年第8期756-760,共5页 Chinese Journal of Hypertension
关键词 Krüppel样转录因子2 动脉粥样硬化 易损斑块 阿托伐他汀 Krtippel-like factor 2 Atherosclerosis Vulnerable plague Atorvastatin
分类号 R543.5 [医药卫生—心血管疾病]
  • 相关文献

参考文献9

  • 1Atkins GB, Jain MK. Role of Krtippel-like transcription factors in endothelial biology[J]. Cire Res, 2007,100(12) : 1686-1695.
  • 2Parmar KM, Larman HB, Dai G, et al. Integration of flow-de- pendent endothelial phenotypes by Krtippel-like factor 2[J]. J Clin Invest,2006,116(1) :49-58.
  • 3Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous de- ficiency of Kriippel-like factor 2 augments experimental atheroscle- rosis[J]. Circ Res,2008,103(7) ：690-693.
  • 4Sen-Banerjee S, Mir S, Lin Z, et al. Kriippel-like factor 2 as a no- vel mediator of statin effects in endothelial cells[J]. Circulation, 2005,112(5) : 720-726.
  • 5Lin H, Xiao Y, Chen G, et al. HMG-CoA reductase inhibitor simvastatin suppresses toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in mono- cytes from rheumatoid arthritis patients[J]. Rheumatol In：, 2011,31(11)：1451-1458.
  • 6Kato K, Otsuka T, Matsushima-Nishiwaki R, et al. Rho-kinase regulates thrombin-stimulated interleukin-6 synthesis via p38 mi- togen-activated protein kinase in osteoblasts[J]. Int J Mol Med, 2011,28(4) : 653-658.
  • 7Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat[J]. Circulation,2006,114(9) :929-935.
  • 8Zahlten J, Steinicke R, Opitz B, et al. TLR2- and nucleotide： binding oligomerization domain 2-dependent Krtippel-like factor 2 expression downregulates NF-kappa B-related gene expression[J]. J Immunol,2010,185(1) ：597-604.
  • 9Egorova AD, Van der Heiden K, Van de Pas S, et al. TGFbeta/ Alk5 signaling is required for shear stress induced KLF2 expres- sion in embryonic endothelial cells[J]. Dev Dyn, 2011,240 (7) : 1670-1680.

同被引文献27

  • 1Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7) / Mas pathway in the brain: the axis of good [J]. Am J Physiol Regul Integr Comp Physiol, 2011, 300 (4):804- 817.
  • 2Tikellis C, Bernardi S, Burns W C. Angiotensin-conver- ting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease[ J]. Curr Opin Nephrol Hypertens, 2011, 20( 1 ) :62-68.
  • 3Bindom S M, Hans C P, Xia H, et al. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice[J]. Diabetes, 2010, 59 (10) :2540-2548.
  • 4Purushothaman K R, Krishnan P, Purushothaman M, et al. Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic athero- ma: implications for inflammation and neovascularization [J]. Cardiovasc Pathol, 2013, 22(1):42-48.
  • 5Zhang C, Zhao Y X, Zhang Y H, et al. Angiotensin- converting enzyme 2 attenuates atherosclerofic lesions by targeting vascular cells [ J ]. Proc Natl Acad Sci U S A, 2010, 107(36) :15886-15891.
  • 6Wang Y, Tikellis C, Thomas M C, et al. Angiotensin converting enzyme 2 and atherosclerosis [ J]. Atheroscle- rosis, 2013, 226(1):3-8.
  • 7Lo C S, Liu F, Shi Y, et al. Dual RAS blockade normal- izes angiotensin-converting enzyme-2 expression and pre- vents hypertension and tubular apoptosis in Akita angio- tensinogen-transgenic mice[ J]. Am J Physiol Renal Phys- iol, 2012, 302(7):840-852.
  • 8Moon J Y. ACE2 and angiotensin-( 1-7 ) in hypertensive renal disease[J]. Electrolyte Blood Press, 2011, 9(2) : 41-44.
  • 9Thatcher S E, Zhang X, Howatt D A, et al. Angioten- sin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice[J]. Arterioscler Thromb Vasc Biol, 2011, 31 (4) :758-765.
  • 10Tikellis C, Pickering R, Tsorotes D, et al. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes [J]. Clin Sci ( Lond), 2012, 123(8) :519-529.

引证文献2

二级引证文献3

中华高血压杂志
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部